Laboratory work using novel cellular research techniques has revealed a better understanding of how neurons communicate with each other in the brain and how to maintain their health. This neuron communication, which involves chemical and electronic transmission methods, is necessary for the brain to function and for neurons to stay healthy and not succumb to cognition loss diseases, such as Alzheimer’s.
With this discovery, a number of similar compounds were found by ADispell to interact in the desired way prescribed by the invention and that can enhance cognition and neuron health. In addition, lead compounds can cause increased blood flow to the brain, a factor that can improve brain performance and health. In addition, some of the lead compounds result in other beneficial behavior, such as an anti-anxiety effect; a plus in treating cognitive loss diseases.
As ADispell has shown with multiple in vivo studies, use of the company’s lead compounds does result in noticeably improved cognition performance – the results sought with Alzheimers, Parkinsons, and patients of other diseases and disorders.
Proprietary rights to this technology are protected by a series of patents licensed and owned by ADispell.
Status of Technology
Three key compounds have been identified as having the characteristics of leads. Each has the properties to act as per the ADispell mechanism and improve brain performance, thus allowing neurons to function more effectively and potentially halting the advancement of cognition loss.
The company has recently completed in vivo experiments with very exciting results. Animals impaired in a way similar to AD’s effects and aged rats both showed significantly enhanced cognition performance. In addition, the animals showed improvement in other behaviors relevant to diseases with cognition loss.
The company sees this as a platform technology as it has potential to treat multiple diseases and conditions related to cognition loss, behavioral treatment, and drug addiction areas.
This novel work is in the ‘Lead Optimization’ phase of the new drug discovery process and has significant in vivo results in hand. We now intend to move this exciting discovery to market as quickly as possible.
We are glad to provide additional information about our technology. Please send a request to firstname.lastname@example.org and let us know about your interest in the technology and our company.